| 1 |
35410313 | Targeting FcγRIIB by antagonistic antibody BI-1206 improves the efficacy of rituximab-based therapies in aggressive mantle cell lymphoma. | 2022 Apr 11 |
1 |
| 2 |
31406628 | Ibrutinib inhibits antibody dependent cellular cytotoxicity induced by rituximab or obinutuzumab in MCL cell lines, not overcome by addition of lenalidomide. | 2019 |
3 |
| 3 |
29750146 | Sensitive Detection of the Natural Killer Cell-Mediated Cytotoxicity of Anti-CD20 Antibodies and Its Impairment by B-Cell Receptor Pathway Inhibitors. | 2018 |
1 |
| 4 |
30089638 | Cellular Cytotoxicity of Next-Generation CD20 Monoclonal Antibodies. | 2018 Oct |
1 |
| 5 |
28810856 | Ibrutinib continues to influence the therapeutic landscape of chronic lymphocytic leukemia: new data presented at ASCO 2017. | 2017 Aug 16 |
1 |
| 6 |
26841018 | Combination of Targeted Drugs to Control Chronic Lymphocytic Leukemia: Harnessing the Power of New Monoclonal Antibodies in Combination With Ibrutinib. | 2016 Jan-Feb |
1 |
| 7 |
27980307 | Genetic and Epigenetic Modulation of CD20 Expression in B-Cell Malignancies: Molecular Mechanisms and Significance to Rituximab Resistance. | 2016 |
1 |
| 8 |
25344523 | Ibrutinib interferes with the cell-mediated anti-tumor activities of therapeutic CD20 antibodies: implications for combination therapy. | 2015 Jan |
4 |
| 9 |
25042202 | Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study. | 2014 Aug |
2 |